First human test of oral e. coli vaccine begins
NCT ID NCT01147445
Summary
This early-stage study tested the safety and immune response of a new oral vaccine designed to protect against diarrhea caused by harmful E. coli bacteria. Thirty-six healthy adults received one of several doses of the experimental vaccine to find the highest dose that did not cause severe side effects. Researchers measured safety and whether the vaccine triggered protective antibodies in the blood and gut.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTERITIS ESCHERICHIA COLI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital Medical Center - Gastroenterology, Hepatology and Nutrition
Cincinnati, Ohio, 45229-3026, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
Conditions
Explore the condition pages connected to this study.